Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Molecular Pathology
  • View item
  • Home
  • ICR Divisions
  • Molecular Pathology
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Streamlining Detection of Fusion Genes in Colorectal Cancer: Having "Faith" in Precision Oncology in the (Tissue) "Agnostic" Era.

Thumbnail
View/Open
Accepted version (155.6Kb)
Date
2019-03
ICR Author
Valeri, Nicola
Author
Valeri, N
Type
Journal Article
Metadata
Show full item record
Abstract
The FDA recently granted tissue-agnostic approval for the first-in-class TRK inhibitor larotrectinib for patients whose tumors harbor fusions in neurotrophic receptor tyrosine kinases. These fusion genes have a frequency of less than 1% in unselected patients with colorectal cancer. Using a multiomics approach and a clinically annotated cohort of patients with colorectal cancer, Cocco and colleagues showed that patients with sporadic, RAS/BRAF wild-type, mismatch repair-deficient colorectal cancer tumors with MLH1 promoter methylation present fusions in kinase genes in 42% of cases and suggested a diagnostic framework to improve the selection of patients eligible for gene fusion testing.See related article by Cocco et al., p. 1047.
URI
https://repository.icr.ac.uk/handle/internal/3212
DOI
https://doi.org/10.1158/0008-5472.can-19-0305
Collections
  • Molecular Pathology
Research team
Gastrointestinal Cancer Biology and Genomics
Language
eng
Date accepted
2019-01-28
License start date
2019-03
Citation
Cancer research, 2019, 79 (6), pp. 1041 - 1043

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.